Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease. The company also announced that the World Health Organization has approved emiltatug ledadotin as XMT-1660s international nonproprietary name.
In a separate announcement, Mersana Therapeutics revealed encouraging preliminary clinical results from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin, which is Mersana's leading Dolasynthen ADC candidate aimed at B7-H4.
"We are confident that the preliminary data regarding the safety, tolerability, and effectiveness of Emi-Le suggest promising outcomes."
showcase a profile that stands out and is engaging in relation to B7-H4.
According to Martin Huber, the CEO of Mersana Therapeutics, the field and the wider ADC landscape are evolving rapidly.
For additional health-related updates, check out rttnews.com.
For comments and feedback contact: [email protected]
